Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Nov;21(11):2169-2174.
doi: 10.1093/annonc/mdq220. Epub 2010 Apr 28.

Survival differences among women with de novo stage IV and relapsed breast cancer

S Dawood  1 , K Broglio  2 , J Ensor  2 , G N Hortobagyi  3 , S H Giordano  3
Affiliations
Comparative Study

Survival differences among women with de novo stage IV and relapsed breast cancer

S Dawood et al. Ann Oncol. 2010 Nov.

Abstract

Background: The objective of this retrospective study was to determine whether differences in survival exist between women with de novo stage IV and relapsed breast cancer.

Patients and methods: Three thousand five hundred and twenty-four women with de novo stage IV or relapsed breast cancer diagnosed from 1992 to 2007 were identified. Disease-free interval (DFI) was defined as the time from the diagnosis of primary nonmetastatic breast cancer to the date of the first distant metastases. Kaplan-Meier product limit method was used to estimate overall survival (OS). Cox proportional hazards model was fitted to determine the association between metastatic disease (relapsed versus de novo) and OS after controlling for other patient/tumor characteristics.

Results: Six hundred and forty-three (18.2%) women had de novo stage IV disease and 2881 (81.8%) had relapsed disease. Median follow-up was 19 months. Median OS among patients with de novo stage IV and relapsed disease was 39.2 and 27.2 months, respectively (P < 0.0001). In the multivariable model, women with relapsed disease had an increased risk of death compared with patients with de novo disease (HR = 1.75, 95% confidence interval 1.47-2.08, P < 0.0001). When the multivariable model was stratified by DFI, women with relapsed disease with DFI <6 months, ≥6 months to <2 years, or ≥2 to <5 years each had a significantly higher risk of death compared with women with de novo stage IV disease. The risk of death was not statistically different among patients with relapsed disease with DFI >5 years compared with those with de novo disease.

Conclusions: This large cohort study provides further insight into the natural history of relapsed and de novo stage IV breast cancer. DFI plays an important role in the prognosis for patients with relapsed breast cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier curves illustrating overall survival for patients with de novo stage IV versus relapsed disease.
Figure 2.
Figure 2.
Kaplan–Meier curves illustrating overall survival for patients with de novo stage IV disease and those with relapsed disease. Patients with relapsed disease are stratified by disease-free interval.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–249. - PubMed
    1. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: De Vitta VT Jr, Hellman S, Rosenberg SA, editors. Cancer. Principles and Practice in Oncology. 4th edition. Philadelphia, PA: JB Lippincott; 1993. pp. 1264–1332.
    1. Miller KD, Sledge GW., Jr The role of chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 1999;13:415–434. - PubMed
    1. Norton L. Metastatic breast cancer: length and quality of life. N Engl J Med. 1991;325:1370–1371. - PubMed
    1. Cardoso F, Di LA, Lohrisch C, et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol. 2002;13:197–207. - PubMed

Publication types

MeSH terms